FDA applicant

Roche

Indianapolis, IN3 decisions2011–20134 recalls

FDA records 3 decisions for Roche (Indianapolis, IN) from 2011 to 2013: 2 510(k) clearances and 1 original PMA approval. Most are in product codes LCP (Assay, Glycosylated Hemoglobin) and LPS (Urinary Homocystine (Nonquantitative) Test…). Its devices cite 4 predicates, 0 of them its own earlier devices. 4 recalls are linked to its devices.

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) refreshed weekly, last Nov 3, 2026

FIG. A — Illustration, hematology panel, where it files most

How often FDA has decided Roche’s devices, and how often a recall has named them.

FDA decisions per year

1in 2013

2011high 1 (2011) · low 0 (2014)2026

2026 so far, outlined.

Recalls per year

1in 2024

2011high 2 (2015) · low 0 (2011)2026

Class I Class II/III not classified

FIG. 1 — Roche by year, 2011–2026Sources: FDA decision databases, recall and enforcement reports · Data through Oct 25, 2026

Planning a device like Roche’s? A 510(k) Report ranks candidate predicates for your device by lineage, citations and recall history, with the review-time outlook.

See the 510(k) Report

Other applicant names beginning “Roche”

FDA records each applicant name separately; these may or may not be the same firm.

Roche Diagnostics Corp. 480 Roche Diagnostic Systems, Inc. 296 Roche Molecular Systems, Inc. 70 Roche Medical Electronics, Inc. 16 Roche Diagnostics Operations (Rdo) 14 Roche Diabetes Care, Inc. 13 Roche Analytical Instruments, Inc. 11 Roche Diagnostics Operations 9 Roche Diagnostics/Boehringer Mannheim GmbH 3 Roche Professional Diagnostics 2 Roche Molecular System, Inc. 1 Roche Image Analysis Systems 1

Roche

Which product codes does it file in?

Whose devices does it build on?

What has FDA decided for it lately?

What has been recalled?

Other applicant names beginning “Roche”